MNKD MANNKIND CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 899460 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.7%
TTM net income YoY-356.0%
TTM EPS YoY-340.0%
Revenue 3-yr CAGR32.8%
Net income 3-yr CAGR—
Margins
Gross margin88.6%
Operating margin-2.9%
Net margin-18.1%
FCF margin-19.0%
EBITDA margin1.1%
Returns
ROE—
ROA-12.3%
ROIC (approx.)-10.5%
Asset turnover0.68x
Leverage & solvency
Liabilities / assets105.2%
Debt / equity—
Current ratio2.22x
Interest coverage-0.34x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $101.87M | $109.37M | $90.17M | $111.95M | $82.13M | $76.53M | $78.35M | $76.78M |
| Cost of revenue | $11.21M | $14.41M | $7.51M | $13.93M | $4.50M | $4.61M | $3.77M | $4.81M |
| Gross profit | $90.66M | $94.97M | $82.66M | $98.03M | $77.63M | $71.92M | $74.59M | $71.97M |
| R&D expense | $14.36M | $18.00M | $17.23M | $27.59M | $14.06M | $13.68M | $11.02M | $11.14M |
| SG&A expense | $61.41M | $58.30M | $54.09M | $58.41M | $29.09M | $31.62M | $25.01M | $60.16M |
| Operating income | -$2.18M | -$350,000 | -$1.67M | -$7.69M | $18.90M | $5.30M | $22.29M | $26.50M |
| Interest expense | $7.64M | $11.89M | $7.48M | $7.54M | $1.36M | $285,000 | $4.64M | $1.56M |
| Pretax income | -$23.17M | -$19.14M | -$16.37M | -$20.93M | $7.78M | $940,000 | $13.62M | $8.45M |
| Income tax | $51,000 | -$106,000 | $253,000 | -$4.98M | -$204,000 | $272,000 | $459,000 | $1.02M |
| Net income | -$23.22M | -$19.03M | -$16.62M | -$15.95M | $7.99M | $668,000 | $13.16M | $7.42M |
| EBITDA | -$112,000 | $1.68M | $4.71M | -$1.66M | $20.91M | $7.34M | $24.40M | $28.66M |
| EPS (basic) | -0.07 | -0.06 | -0.05 | — | 0.03 | 0.00 | 0.04 | — |
| EPS (diluted) | -0.07 | -0.06 | -0.05 | — | 0.03 | 0.00 | 0.04 | — |
| Weighted avg. shares (diluted) | 320.18M | 309.19M | 308.27M | — | 311.64M | 311.48M | 320.90M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.28M | $52.93M | $52.83M | $74.88M | $127.39M | $57.01M | $47.31M | $46.34M |
| Short-term investments | $55.33M | $58.20M | $81.03M | $96.46M | $132.64M | $121.98M | $134.23M | $150.92M |
| Receivables | $41.03M | $43.21M | $28.14M | $38.37M | $17.38M | $27.14M | $28.90M | $11.80M |
| Inventory | $48.47M | $44.42M | $49.17M | $35.31M | $26.97M | $28.49M | $28.89M | $27.89M |
| Current assets | $240.48M | $245.71M | $251.16M | $291.58M | $358.84M | $279.03M | $273.74M | $268.31M |
| PP&E, net | $86.37M | $85.16M | $82.55M | $82.42M | $82.65M | $82.97M | $83.78M | $85.36M |
| Goodwill | $67.59M | $67.59M | $67.59M | $67.59M | $1.93M | $1.93M | $1.93M | $1.93M |
| Intangibles | $4.93M | $4.98M | $5.02M | $5.07M | $5.12M | $5.17M | $5.22M | $5.26M |
| Total assets | $722.62M | $732.30M | $744.40M | $792.18M | $494.64M | $411.70M | $410.14M | $393.84M |
| Current liabilities | $108.52M | $142.90M | $134.56M | $171.03M | $109.13M | $111.83M | $115.94M | $81.84M |
| Long-term debt | $319.45M | $319.08M | $318.72M | $354.64M | $109.65M | $36.17M | $36.11M | $36.05M |
| Total debt | $319.45M | $319.08M | $318.72M | $354.64M | $109.65M | $36.17M | $36.11M | $36.05M |
| Total liabilities | $759.88M | $799.50M | $803.60M | $843.20M | $539.19M | $466.74M | $468.76M | $472.66M |
| Shareholders' equity | -$37.27M | -$67.20M | -$59.20M | -$51.02M | -$44.55M | -$55.04M | -$58.62M | -$78.82M |
| Net debt | $278.17M | $266.16M | $265.89M | $279.76M | -$17.74M | -$20.84M | -$11.20M | -$10.29M |
| Shares outstanding | 321.63M | 309.91M | 308.91M | 307.83M | 307.03M | 306.33M | 303.92M | 302.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$34.55M | -$18.37M | -$5.37M | -$7.96M | $23.64M | $8.95M | -$6.38M | $22.64M |
| Capital expenditure | $3.21M | $5.08M | $1.88M | $1.99M | $1.12M | $1.12M | $330,000 | $2.90M |
| Free cash flow | -$37.76M | -$23.45M | -$7.25M | -$9.95M | $22.52M | $7.83M | -$6.71M | $19.75M |
| Investing cash flow | -$252,000 | $17.91M | $18.73M | -$291.96M | -$25.06M | $6.26M | $5.96M | $48.22M |
| Financing cash flow | $23.15M | $559,000 | -$35.41M | $247.41M | $71.81M | -$5.51M | $1.39M | -$86.90M |
| Depreciation & amortization | $2.07M | $2.03M | $6.38M | $6.03M | $2.01M | $2.04M | $2.11M | $2.16M |
| Stock-based compensation | $6.44M | $10.23M | $6.46M | $6.97M | $4.32M | $7.52M | $5.38M | $5.82M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.